Telemedicine During the COVID-19 Pandemic: Impact on Care for Rare Cancers
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
PURPOSE: Many patients with cancer, often those with rare cancers such as sarcomas, travel long distances to access expert care. The COVID-19 pandemic necessitated widespread changes in delivery of cancer care, including rapid adoption of telemedicine-based care. We aimed to evaluate the impact of telemedicine on patients, clinicians, and care delivery at the Royal Marsden Hospital (RMH) Sarcoma Unit during the pandemic. METHODS: Data were extracted from patient records for all planned outpatient appointments at the RMH Sarcoma Unit from March 23 to April 24, 2020. Patients and clinicians completed separate questionnaires to understand their experiences. RESULTS: Of 379 planned face-to-face appointments, 283 (75%) were converted to telemedicine. Face-to-face appointments remained for patients who needed urgent start of therapy or performance status assessment. Patients lived on average > 1.5 hours from RMH. Patient satisfaction (n = 108) with telemedicine was high (mean, 9/10), and only 48% (n = 52/108) would not want to hear bad news using telemedicine. Clinicians found telemedicine efficient, with no associated increased workload, compared with face-to-face appointments. Clinicians indicated lack of physical examination did not often affect care provision when using telemedicine. Most clinicians (n = 17; 94%) believed telemedicine use was practice changing; congruently, 80% (n = 86/108) of patients desired some telemedicine as part of their future care, citing reduced cost and travel time. CONCLUSION: Telemedicine can revolutionize delivery of cancer care, particularly for patients with rare cancers who often live far away from expert centers. Our study demonstrates important patient and clinician benefits; assessment of longer-term impact on patient outcomes and health care systems is needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meeting the ongoing needs of survivors of rarer cancer
Griffiths, J., Willard, C., Burgess, A., Amir, Z., & Luker, K. (2007) · European Journal of Oncology Nursing · doi:10.1016/j.ejon.2007.09.004 · Cited by 24
Cited by
Telehealth utilization during the Covid-19 pandemic: a systematic review
Garfan, S., Alamoodi, A. H., Zaidan, B. B., Al-Zobbi, M., Hamid, R. A., Alwan, J. K., Ahmaro, I. Y. Y., Khalid, E. T., Jumaah, F. M., Albahri, O. S., et al. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104878 · Cited by 369
Satisfaction with the use of telehealth during COVID-19: An integrative review
Andrews, E., Berghofer, K., Long, J., Prescott, A., & Caboral-Stevens, M. (2020) · International Journal of Nursing Studies Advances · doi:10.1016/j.ijnsa.2020.100008 · Cited by 216
Nanda, M., & Sharma, R. (2021) · Telemedicine and e-Health · doi:10.1089/tmj.2020.0570 · Cited by 211
Rural telemedicine use before and during the COVID-19 pandemic: repeated cross-sectional study.
Chu, C., Cram, P., Pang, A., Stamenova, V., Tadrous, M., & Bhatia, R. S. (2021) · Journal of Medical Internet Research · doi:10.2196/26960 · Cited by 183
Chan, R. J., Crichton, M., Crawford-Williams, F., Agbejule, O. A., Yu, K., Hart, N. H., de Abreu Alves, F., Ashbury, F. D., Eng, L., Fitch, M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.09.001 · Cited by 144
Metadata
- Authors
- Smrke, A., Younger, E., Wilson, R., Husson, O., Farag, S., Merry, E., Macklin-Doherty, A., Cojocaru, E., Arthur, A., Benson, C., Miah, A. B., Zaidi, S., Gennatas, S., & Jones, R. L.
- Venue
- JCO Global Oncology
- Published
- 2020-11
- Volume
- 6
- Issue
- 6
- Pages
- 1046-1051
- ISSN
- 2687-8941 (ISSN-L)
- OpenAlex
- W3040826030
- Cited by
- 106
- References
- 1
- FWCI
- 16.00
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.